Preclinical and clinical evaluation of recombinant human macrophage colony-stimulating factor (rhM-CSF).
The promise of hematopoietic growth factors is now being realized as clinical trials become more mature. The uses of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor are now becoming more established in therapeutic applications of disease states. A variety of new hematopoietic growth factors is on the horizon, including recombinant human macrophage colony-stimulating factor (rhM-CSF), which has recently entered clinical trials after extensive preclinical testing. The diverse biological actions of rhM-CSF will provide novel ways of approaching various medical problems across the disciplines of hematology, oncology, infectious disease and cardiology.
Garnick
M B
MB
Genetics Institute, Cambridge, Massachusetts 02140.
Stoudemire
J B
JB
D000818:Animals; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D006801:Humans; D066298:In Vitro Techniques; D016173:Macrophage Colony-Stimulating Factor; D008264:Macrophages / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use
D003115:Colony-Stimulating Factors; D011994:Recombinant Proteins; D016173:Macrophage Colony-Stimulating Factor